DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
HOUSTON, March 06, 2018 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the 30th Annual ROTH Conference on Tuesday, March 13, 2018 at 10:35 a.m. PT in Dana Point, CA.
A live webcast of the presentation can be accessed under “Presentations and Publications” in the Media section of the Company’s website at www.biopathholdings.com.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
